Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и постковидный синдром

Пандемия COVID-19 спровоцировала вторую пандемию, «постковидную», у лиц с сохраняющимися симптомами после острого периода коронавирусной инфекции. Большинство пациентов, страдающих коронавирусной инфекцией, полностью выздоравливают в среднем в течение двух недель, однако примерно каждый десятый человек испытывает долгосрочные симптомы со стороны ряда систем организма, в том числе дыхательной, сердечно-сосудистой и нервной, а также сталкивается с психологическими последствиями. Симптомы постковидного синдрома неоднородные, многочисленные и сложны в интерпретации. В настоящее время стандартизированных методов диагностики и общепринятых критериев верификации постковидного синдрома нет. В начале октября 2021 года ВОЗ представила универсальное определение постковидного синдрома или постковидных состояний. Высокая распространенность артериальной гипертонии среди пациентов с COVID-19 диктует необходимость наблюдения данной категории пациентов, в том числе и в рамках постковидного синдрома. В консенсусе экспертов Российского медицинского общества по артериальной гипертонии представлены имеющиеся данные об эпидемиологии, факторах риска и патофизиологии постковидного синдрома. Проанализированы возможные механизмы поражения сердечно-сосудистой системы при данном синдроме. Отдельное внимание уделено особенностям течения и клиническим проявлениям артериальной гипертонии при постковидном синдроме, патофизиологическим аспектам дестабилизации артериального давления и тактике ведения данной категории пациентов.

1. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/

2. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18. PMID: 33555768.

3. Fernández-de-Las-Peñas C., Palacios-Ceña D., Gómez-Mayordomo V. et al. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int J Environ Res Public Health. 2021 Mar 5;18(5):2621. https://doi:10.3390/ijerph18052621

4. Fernández-de-Las-Peñas C., Florencio L.L., Gómez-Mayordomo V. et al. Proposed integrative model for post-COVID symptoms. Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102159. Epub 2021 Jun 1. https://doi.org/10.1016/j.dsx.2021.05.032

5. Diaz Janet V. and Joan B. Soriano. A Delphi consensus to advance on a Clinical Case Definition for Post COVID-19 condition: A WHO protocol. (2021) https://doi.org/10.21203/rs.3.pex-1480/v1

6. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. http://WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1

7. https://www.who.int/srilanka/news/detail/16-10-2021-post-covid-19-condition

8. Sivan M., Rayner C., Delaney B. Fresh evidence of the scale and scope of long covid. BMJ. 2021 Apr 1;373:n853. https://doi.org/10.1136/bmj.n853

9. Chopra V., Flanders S.A., O'Malley M. et al. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. Ann Intern Med. 2021 Apr;174(4):576-578. Epub 2020 Nov 11. https://doi.org/10.7326/M20-5661

10. Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617. Update in: Sci Rep. 2021 Aug 9;11(1):16144. https://doi.org/10.1101/2021.01.27.21250617

11. Becker R.C. COVID-19 and its sequelae: a platform for optimal patient care, discovery and training. J Thromb Thrombolysis. 2021 Apr;51(3):587-594. Epub 2021 Jan 27. https://doi.org/10.1007/s11239-021-02375-w

12. Fernández-de-Las-Peñas C., Palacios-Ceña D., Gómez-Mayordomo V. et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Intern Med. 2021 Oct;92:55-70. Epub 2021 Jun 16. https://doi.org/10.1016/j.ejim.2021.06.009

13. Salamanna F., Veronesi F., Martini L. et al. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med (Lausanne). 2021 May 4;8:653516. https://doi.org/10.3389/fmed.2021.653516

14. Halpin S.J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021 Feb;93(2):1013-1022. Epub 2020 Aug 17. https://doi.org/10.1002/jmv.26368

15. Taboada M., Cariñena A., Moreno E. et al. Post-COVID-19 functional status six-months after hospitalization. J Infect. 2021 Apr;82(4):e31-e33. Epub 2020 Dec 26. https://doi:10.1016/j.jinf.2020.12.022

16. Stavem K., Ghanima W., Olsen M.K. et al. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2021 Apr;76(4):405-407. Epub 2020 Dec 3. https://doi:10.1136/thoraxjnl-2020-216377

17. Moreno-Pérez O., Merino E., Leon-Ramirez J.M. et al. COVID19-ALC research Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021 Mar;82(3):378-383. Epub 2021 Jan 12. https://doi:10.1016/j.jinf.2021.01.004

18. Dennis A., Wamil M., Alberts J. et al.; COVERSCAN study investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021 Mar 30;11(3):e048391. https://doi:10.1136/bmjopen-2020-048391

19. Mohanty A., Kabi A., Mohanty A.P. et al. Laboratory diagnosis of COVID-19 infection: Issues and Challenges: An Indian Perspective; Journal of Advances in Medicine and Medical Research. 2020; 32(14):10-17

20. Mohanty A., Kabi A., Kumar S. et al. Role of rapid antigen test in the diagnosis of COVID19 in India. Journal of Advances in Medicine and Medical Research 2020; 32(18):77-80. https://doi:10.9734/jammr/2020/v32i1830657

21. Antonelli M., Pujol J.C., Spector T.D. et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. The Lancet. 2022;399:2263–4. https://doi:10.1016/S0140-6736(22)00941-2

22. Thompson E.J., Williams D.M., Walker A.J. et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. 2021. published online Jan 1. (preprint). https://doi.org/10.1101/2021.06.24.21259277

23. Whitaker M., Elliott J., Chadeau-Hyam M. et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 2021. published online Jan 1. (preprint). https://doi.org/10.1101/2021.06.28.21259452

24. Su Y., Yuan D., Chen D.G. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022 Mar 3;185(5):881-895.e20. Epub 2022 Jan 25. https://doi.org/10.1016/j.cell.2022.01.014

25. Sigfrid L., Drake T.M., Pauley E. et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Lancet Reg Health Eur. 2021 Sep;8:100186. Epub 2021 Aug 6. https://doi.org/10.1016/j.lanepe.2021.100186

26. Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–615. https://doi.org/10.1038/s41591-021-01283-z

27. Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013 Dec;13(12):862-74. Epub 2013 Nov 15. https://doi.org/10.1038/nri3552

28. Hamers L., Kox M., Pickkers P. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol. 2015 Apr;81(4):426-39.

29. Groff D., Sun A., Ssentongo A.E. et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open. 2021 Oct 1;4(10):e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568

30. Huang C., Huang L., Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. Epub 2021 Jan 8. https://doi.org/10.1016/S0140-6736(20)32656-8

31. Arnold D.T., Hamilton F.W., Milne A. et al. Patient outcomes after hospitalization with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021 Apr;76(4):399-401. Epub 2020 Dec 3. https://doi.org/10.1136/thoraxjnl-2020-216086

32. Chippa V., Aleem A., Anjum F. Post Acute Coronavirus (COVID-19) Syndrome. [Updated 2022 Jun 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570608/

33. Dixit N.M., Churchill A., Nsair A. et al. Post-Acute COVID-19 Syndrome and the cardiovascular system: What is known? Am Heart J Plus. 2021 May;5:100025. Epub 2021 Jun 24. https://doi.org/10.1016/j.ahjo.2021.100025

34. Ziauddeen N., Gurdasani D., O’Hara M.E. et al. Characteristics of long covid: findings from a social media survey. medRxiv 2021. https://doi.org/10.1101/2021.03.21.21253968

35. Fu H., Zhang N., Zheng Y. et al. Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients. J Infect. 2021 Jul;83(1):119-145. Epub 2021 Apr 19. https://doi.org/10.1016/j.jinf.2021.04.016

36. Raj S.R., Arnold A.C., Barboi A. et al. American Autonomic Society. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clin Auton Res. 2021 Jun;31(3):365-368. Epub 2021 Mar 19. https://doi.org/10.1007/s10286-021-00798-2

37. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 Jun;594(7862):259-264. Epub 2021 Apr 22. https://doi.org/10.1038/s41586-021-03553-9

38. Martinez M.W., Tucker A.M., Bloom O.J. et al. Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening. JAMA Cardiol. 2021 Jul 1;6(7):745-752. https://doi.org/10.1001/jamacardio.2021.0565

39. Ayoubkhani D., Khunti K., Nafilyan V. et al. Thomas Maddox, Ben Humberstone, Sir Ian Diamond, Amitava Banerjee Epidemiology of post-COVID syndrome following hospitalization with coronavirus: a retrospective cohort study. https://doi.org/10.1101/2021.01.15.21249885

40. Katsoularis I., Fonseca-Rodríguez O., Farrington Р. et al. Risk of acute myocardial infarction and ischaemic strokefollowing COVID-19 in Sweden: a self-controlled case series and matched cohort study. Published Online July 29, 2021. https://doi.org/10.1016/S0140-6736(21)00896-5

41. Sui Y., Li J., Venzon D.J. et al. SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage. Front Immunol. 2021 Jun 4;12:658428. https://doi.org/10.3389/fimmu.2021.658428

42. Ingraham N.E., Barakat A.G., Reilkoff R. et al. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review. Eur Respir J. 2020 Jul 9;56(1):2000912. https://doi.org/10.1183/13993003.00912-2020

43. Cooper S.L., Boyle E., Jefferson S.R. et al. Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int J Mol Sci. 2021 Jul 31;22(15):8255. https://doi.org/10.3390/ijms22158255

44. Liang L., Yang B., Jiang N. et al. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J Korean Med Sci. 2020 Dec 7;35(47):e418. https://doi.org/10.3346/jkms.2020.35.e418

45. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020 Aug 11;324(6):603-605. https://doi.org/10.1001/jama.2020.12603

46. Pavli A., Theodoridou M., Maltezou H.C. Post-COVID Syndrome: Incidence, Clinical Spectrum, and Challenges for Primary Healthcare Professionals. Arch Med Res. 2021 Aug;52(6):575-581. Epub 2021 May 4. https://doi.org/10.1016/j.arcmed.2021.03.010

47. Mohiuddin Chowdhury A.T.M., Karim M.R., Ali M.A. et al. Clinical Characteristics and the Long-Term Post-recovery Manifestations of the COVID-19 Patients-A Prospective Multicenter Cross-Sectional Study. Front Med (Lausanne). 2021 Aug 17;8:663670. https://doi.org/10.3389/fmed.2021.663670

48. Wang Y.F., Wang S.J. Hypertension and Migraine: Time to Revisit the Evidence. Curr Pain Headache Rep. 2021 Jul 16;25(9):58. https://doi.org/10.1007/s11916-021-00976-x

49. Fernández-de-Las-Peñas C., Torres-Macho J., Velasco-Arribas M. et al. Preexisting hypertension is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: a case-control study. J Hum Hypertens. 2022 Jun;36(6):582-584. Epub 2022 Feb 16. https://doi.org/10.1038/s41371-022-00660-6

50. Grasselli G., Zangrillo A., Zanella A. et al. COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574-1581. Erratum in: JAMA. 2021 May 25;325(20):2120. https://doi.org/10.1001/jama.2020.5394

51. Bosso M., Thanaraj T.A., Abu-Farha M. et al. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Mol Ther Methods Clin Dev. 2020 Jun 25;18:321-327. https://doi.org/10.1016/j.omtm.2020.06.017

52. Li J., Wang X., Chen J. et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020 Jul 1;5(7):825-830. Erratum in: JAMA Cardiol. 2020 Aug 1;5(8):968. https://doi.org/10.1001/jamacardio.2020.1624

53. Patel S., Rauf A., Khan H. et al. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017 Oct;94:317-325. Epub 2017 Jul 31. https://doi.org/10.1016/j.biopha.2017.07.091

54. Devaux C.A., Rolain J.M., Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020 Jun;53(3):425-435. Epub 2020 May 6. https://doi.org/10.1016/j.jmii.2020.04.015

55. Drummond G.R., Vinh A., Guzik T.J. et al. Immune mechanisms of hypertension. Nat Rev Immunol. 2019 Aug;19(8):517-532. PMID: 30992524. https://doi.org/10.1038/s41577-019-0160-5

56. Lei Y., Zhang J., Schiavon C.R. et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-1326. Epub 2021 Mar 31. https://doi.org/10.1161/CIRCRESAHA.121.318902

57. Akpek M. Does COVID-19 Cause Hypertension? Angiology. 2022;73(7):682-687. https://doi.org/10.1177/00033197211053903

58. Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond). 2021 Jan;21(1):e63-e67. Epub 2020 Nov 26. https://doi.org/10.7861/clinmed.2020-0896

59. Shouman K., Vanichkachorn G., Cheshire W.P. et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31(3):385–94. https://doi.org/10.1007/s10286-021-00803-8

60. Blitshteyn S., Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205–11. https://doi.org/10.1007/s12026-021-09185-5

61. Konig M.F., Powell M., Staedtke V. et al. Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest. 2020;130(7):3345–7. https://doi.org/10.1172/JCI139642

62. DePace N.L., Colombo J. Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems. Curr Cardiol Rep. 2022 Sep 30:1–16. doi: 10.1007/s11886-022-01786-2. Epub ahead of print.

63. Oz M., Lorke D.E., Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARSCoV-2 entry receptor. Pharmacol Ther. 2021;221:107750. https://doi.org/10.1016/j.pharmthera.2020.107750

64. Nozari F., Hamidizadeh N. The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review. Int J Hypertens. 2022 Jan 21;2022:5937802. https://doi.org/10.1155/2022/5937802